SMC
AXSM icon

Smith, Moore & Co’s Axsome Therapeutics AXSM Stock Holding History

Smith, Moore & Co’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$245K Buy
+1,000
New +$217K 0.02% 515

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Smith, Moore & Co's AXSM Position: Q2 2026 in Review

Smith, Moore & Co opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 1,000 shares worth $245K. The stake represents 0.02% of the portfolio and ranks #515 among its holdings.

504 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Smith, Moore & Co held 1,000 shares of Axsome Therapeutics worth $245K as of Q2 2026.
  • Axsome Therapeutics was a new Smith, Moore & Co position in Q2 2026.
  • Axsome Therapeutics made up 0.02% of Smith, Moore & Co's portfolio in Q2 2026, its #515 holding.
  • 504 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Smith, Moore & Co's 13F filing for Q2 2026, filed 12 Aug 2026.